Company intelligence / Profile preview

Pulmovant

Waltham, Massachusetts, United Statespulmovant.com ↗

Ownership: Private
Development stage: Other

Overview

Pulmovant’s lead asset, mosliciguat, is an inhaled small molecule sGC activator being developed as a once-daily treatment for pulmonary hypertension associated with interstitial lung disease. Phase 1 data showed up to a 38% reduction in pulmonary vascular resistance—one of the highest reductions seen in PH trials to date. The drug is currently being evaluated in a global Phase 2 trial ("PHocus") and has shown promising safety and efficacy signals so far

Therapeutic areas: Pulmonology
Modalities: Small moleculeInhaled drug delivery therapySoluble guanylate cyclase activator (sGC activator)
Industry: Biotech

Drug pipeline

1 asset

mosliciguat

Partnerships

Bayer AG — exclusive worldwide license for mosliciguat

Beyond the preview

Go deeper on Pulmovant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmovant.

Explore the full profile